Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenetic Biosciences Inc XBIO

Healthcare Biotechnology
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the... see more

Recent & Breaking News (NDAQ:XBIO)

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Accesswire 4 days ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Accesswire 5 days ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Accesswire 13 days ago

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Accesswire November 12, 2024

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Accesswire November 7, 2024

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Accesswire October 22, 2024

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Accesswire October 17, 2024

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Accesswire September 11, 2024

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Accesswire August 14, 2024

Xenetic Biosciences, Inc. Announces Executive Leadership Transition

Accesswire May 22, 2024

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Accesswire May 10, 2024

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Accesswire March 22, 2024

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Accesswire January 17, 2024

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Accesswire November 10, 2023

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Accesswire October 11, 2023

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Accesswire September 5, 2023

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

Accesswire August 11, 2023

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

Accesswire July 5, 2023

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

Accesswire May 12, 2023

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Accesswire May 11, 2023